PMID- 1394965
OWN - NLM
STAT- MEDLINE
DCOM- 19921116
LR  - 20190827
IS  - 0165-3806 (Print)
IS  - 0165-3806 (Linking)
VI  - 68
IP  - 2
DP  - 1992 Aug 21
TI  - Pre- and postnatal development of high-affinity [3H]nicotine binding sites in rat 
      brain regions: an autoradiographic study.
PG  - 163-74
AB  - The ontogeny of high affinity nicotinic cholinergic binding sites was studied in 
      Long-Evans rat brain by in vitro autoradiography, using [3H]nicotine (10 nM) and 
      cold (-)nicotine bitartrate to assess specificity. The first binding sites become 
      detectable in spinal cord and caudal medulla oblongata at gestational day (GD) 
      12. Until GD 14, labelling spreads throughout lower brainstem, mesencephalon and 
      parts of diencephalon, with higher densities in ventral areas (including the area 
      of developing mesencephalic dopamine neurons). Matrix zones remain unlabelled. 
      Receptor sites appear in the cerebellar anlage by GD 15, and in caudal 
      caudate-putamen by GD 16. During development from late gestational to early 
      postnatal stages, labelling is reduced in many lower brainstem areas and 
      increases in forebrain, in particular in neocortex. Receptor density remains high 
      in thalamus. In neocortex, nicotinic receptor sites are first seen in the 
      subplate layer by GD 20. Labelling of this zone remains prominent until PN 14, 
      when an additional band of increased receptor density is seen in cortical layers 
      III/IV which contain high receptor levels in adulthood. At PN 27, the pattern has 
      become similar to the adult one. The development of [3H]nicotine-binding sites in 
      individual brain regions, with a general caudo-rostral gradient, accompanies cell 
      differentiation and early synapse formation, e.g., in neocortex. The ontogenetic 
      pattern differs in detail from that of muscarinic-cholinergic binding sites. The 
      early presence of binding sites provides a basis for specific actions of nicotine 
      on the fetal brain. As a consequence of the ontogenetic changes, different brain 
      structures become targets for the action of this drug at different stages of 
      development.
FAU - Naeff, B
AU  - Naeff B
AD  - Institute of Pharmacology, University of Zurich, Switzerland.
FAU - Schlumpf, M
AU  - Schlumpf M
FAU - Lichtensteiger, W
AU  - Lichtensteiger W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Brain Res Dev Brain Res
JT  - Brain research. Developmental brain research
JID - 8908639
RN  - 0 (Receptors, Nicotinic)
RN  - 10028-17-8 (Tritium)
RN  - 6M3C89ZY6R (Nicotine)
SB  - IM
MH  - Animals
MH  - Autoradiography
MH  - Brain/embryology/growth & development/*metabolism
MH  - Embryonic and Fetal Development/physiology
MH  - Gestational Age
MH  - Nicotine/*metabolism
MH  - Rats
MH  - Receptors, Nicotinic/*metabolism
MH  - Tritium
EDAT- 1992/08/21 00:00
MHDA- 1992/08/21 00:01
CRDT- 1992/08/21 00:00
PHST- 1992/08/21 00:00 [pubmed]
PHST- 1992/08/21 00:01 [medline]
PHST- 1992/08/21 00:00 [entrez]
AID - 0165-3806(92)90058-5 [pii]
AID - 10.1016/0165-3806(92)90058-5 [doi]
PST - ppublish
SO  - Brain Res Dev Brain Res. 1992 Aug 21;68(2):163-74. doi: 
      10.1016/0165-3806(92)90058-5.